“Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy Analysis by Baseline Disease Characteristics From the Phase 3 POETYK PSO-1 and PSO-2 Trials” (2021) SKIN The Journal of Cutaneous Medicine, 5(6), p. s36. doi:10.25251/skin.5.supp.36.